Alamar launches commercial eMTBR-Tau blood immunoassay
Alamar Biosciences on July 7, 2026 launched the first commercial eMTBR-Tau immunoassay, the company said in a Globe Newswire release. The assay is included in NULISAseq Neuro 220 multiplexed panel kits, is immediately deployable on the installed base of ARGO HT instruments, and is available as a single-plex through Alamar's Technology Access Program (TAP). eMTBR-Tau is a plasma biomarker that reflects tau tangle pathology and has shown strong associations with cognitive decline, clinical disease staging and therapeutic response monitoring in Alzheimer's disease, potentially enabling more precise patient staging and trial monitoring.
Alamar launched the first commercial eMTBR-Tau immunoassay.
Context
Alamar Biosciences launched the eMTBR-Tau assay on July 7, 2026. The assay is in NULISAseq Neuro 220 kits and can run on ARGO HT instruments or via TAP. Researchers and trial teams could use it next for staging, stratification, and therapy…
The full analysis
19 dimensions on this story — world impact, market read, and what happens next.
- Full ContextLocked
- Affected SectorsLocked
- Stock ImpactLocked
- Economic IndicatorLocked
- Investor RelevanceLocked
- Professional RelevanceLocked
- Watch PointsLocked
- Probability of ChangeLocked
- Debate PointsLocked
- Prerequisite KnowledgeLocked
- Follow-up QuestionsLocked
- Pros & ConsLocked